Scott Riccio

Board Chair

Scott is currently Vice President of Global Patient Advocacy at Synageva Biopharma, a biotechnology company based in Lexington, MA, dedicated to discovering, developing and delivering therapies for patients with rare diseases.  Scott’s responsibilities include building and managing a world-class patient advocacy capability at the company, including ensuring that the patient’s voice is always a leading influence on the company’s culture.  Scott also oversees the development of the company’s government affairs and public policy functions with a focus on ensuring patient access and rare disease patients’ perspectives are included as part of policy in healthcare.

Before taking the position at Synageva, Scott was Senior Vice-President for Patient Access, Education, & Advocacy at The Leukemia & Lymphoma Society, working out of the Office of Public Policy in Washington, D.C.  Scott’s responsibilities for the Society included building a stronger Mission presence for the Society across the country, building and overseeing a team of regional strategic leaders whose focus is on assessing patient needs and deploying resources to meet those needs, and serving as external Mission spokesperson for LLS in supporting campaign and development initiatives– all in the spirit of delivering access to the best care possible for blood cancer patients.

Scott oversaw the Patient Access functions in LLS’ Field Mission Teamas well as the Patient Access Team in LLS’ national office, ensuring an organizational focus on bringing awareness of LLS and its resources to all those in need and to identifying, reducing and/or removing as many barriers to accessing quality, affordable, and coordinated cancer care as possible.  Strategic resources under Scott’s oversight include patient outreach and engagement, HCP/provider relations, patient and professional education, and advocacy.

Prior to LLS, Scott was Associate Director for Advocacy and Health Policy for Dendreon Corporation, focusing on ensuring patient access to innovative anti-cancer therapies while helping strengthen the organizations he worked with in the cancer advocacy community. His work also included outreach and engagement with payers/insurers and healthcare providers and a special focus on underserved groups disproportionately impacted by prostate cancer, specifically African American and Veteran populations.

Scott’s background includes time as the founder and president of a 501(c)3 advocacy organization focused on health policy, particularly FDA/drug development timelines and processes, as well as a decade of experience consulting with global financial institutions during his time at Morningstar Associates, LLC.  He holds a B.A. in political science from Middlebury College and an M.B.A. with a dual concentration in entrepreneurship and strategy from the University of Chicago.

Advisory Board

Sorry, no posts matched your criteria.